HCM
GNMK

Highbridge Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Highbridge Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-33,112
Closed -$391K – 1712
2016
Q3 		$391K Buy
+33,112
New +$320K 0.01% 895

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highbridge Capital Management's GNMK Position: Q4 2016 in Review

Highbridge Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2016, closing a stake of 33,112 shares — an estimated $391K sold.

Highbridge Capital Management first reported a position in GNMK in Q3 2016 and held it in 1 quarter. The position peaked at $391K in Q3 2016. 90 funds tracked by Wall St. Rank hold GNMK as of Q4 2016.

  • Highbridge Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 33,112 GenMark Diagnostics, Inc shares in Q4 2016, an estimated $391K.
  • Highbridge Capital Management first reported a position in GenMark Diagnostics, Inc in Q3 2016 and held it in 1 quarter.
  • Highbridge Capital Management's GenMark Diagnostics, Inc position peaked at $391K in Q3 2016.
  • 90 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.